臓器移植用免疫抑制剤の市場規模、シェア、動向分析レポート：薬剤クラス別、移植タイプ別、地域別、セグメント別予測、2025年～2030年

臓器移植免疫抑制剤市場の成長と動向

Grand View Research, Inc.の最新レポートによると、臓器移植免疫抑制剤の世界市場規模は2025～2030年にかけてCAGR 4.7%を記録し、2030年には72億4,000万米ドルに達すると推定されています。

臓器移植を必要とする患者数の増加や、新規製品の承認が増加していることが市場成長の要因です。しかし、移植の手続き費用が高いこと、臓器の需要と供給の不均衡、不透明な償還シナリオが市場成長を抑制する主要要因となっています。

保健資源サービス庁と米国保健福祉省によると、2019年1月時点で11万3,000人以上が移植を必要としており、2018年には3万6,528件の移植が実施されました。したがって、臓器移植の需要は膨大であり、市場をさらに押し上げると考えられます。腎臓移植は移植セグメントで最大の市場シェアを占め、予測期間を通じてトップの座を維持すると予想されます。これは、需要の増加と、他の臓器よりも腎臓の入手性が比較的良いことに起因しています。

薬剤クラス別では、カルシニューリン阻害剤が予測期間を通じて世界の臓器移植免疫抑制剤市場を独占するとみられます。この薬剤クラス別には、プログラフ（タクロリムス）とサンディミュン（シクロスポリン）の2剤があります。これらの効果的な免疫抑制剤は20年以上にわたって腎移植患者に使用されているが、毒性プロファイルは広範囲に及んでいます。アジア太平洋が最も高いCAGRを示し、北米が予測期間中最大のシェアを占めると予想されています。

臓器移植免疫抑制剤市場レポートハイライト

• 薬剤クラス別では、カルシニューリン阻害剤が最大の市場シェアを占める見込み。カルシニューリン阻害剤は、酵素カルシニューリンによる免疫系T細胞の活性化作用を阻害します。
• タクロリムスやシクロスポリンなどのカルシニューリン阻害剤は、腎移植における免疫抑制の要です。腎移植の85％以上の症例で、タクロリムスは患者の維持免疫抑制レジメンの一部として配合されています。
• 移植タイプ別では、腎移植が2024年に49.1%の最大市場シェアを占めました。
• アジア太平洋市場は、一人当たり医療支出の増加、医療インフラの改善、同地域における臓器移植需要の増加により、予測期間中に最も速い成長を示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 臓器移植免疫抑制剤市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 産業分析-ポーターのファイブフォース分析
  • PESTLE分析

第4章 臓器移植免疫抑制剤市場：薬剤クラスのビジネス分析

• 薬剤クラスの市場シェア、2024年と2030年
• 薬剤クラスセグメントダッシュボード
• 市場規模と予測と動向分析、薬剤クラス別、2018～2030年
• カルシニューリン阻害剤
• 抗増殖剤
• mTOR阻害剤
• ステロイド
• その他

第5章 臓器移植免疫抑制剤市場：移植タイプのビジネス分析

• 移植タイプの市場シェア、2024年と2030年
• 移植タイプセグメントダッシュボード
• 市場規模と予測と動向分析、移植タイプ別、2018～2030年
• 腎臓
• 肝臓
• 心臓
• 肺
• 膵臓
• その他の移植タイプ

第6章 臓器移植免疫抑制剤市場：薬剤クラスによる地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 市場規模と予測動向分析、2018～2030年
• 北米
  • 国別、2018～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 国別、2018～2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • デンマーク
  • スウェーデン
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • 国別、2018～2030年
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 国別、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 参加者概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/上場企業
  • Astellas Pharma doo
  • Sanofi
  • Accord Healthcare
  • Novartis AG
  • Viatris Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Veloxis Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global organ transplant immunosuppressant drugs market, by region, 2018 - 2030 (USD Million)
• Table 4. Global organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 5. Global organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 6. North America organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
• Table 7. North America organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 8. North America organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 9. U.S. organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 10. U.S. organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 11. Canada organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 12. Canada organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 13. Mexico organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 14. Mexico organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 15. Europe organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
• Table 16. Europe organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 17. Europe organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 18. UK organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 19. UK organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 20. Germany organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 21. Germany organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 22. France organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 23. France organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 24. Italy organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 25. Italy organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 26. Spain organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 27. Spain organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 28. Denmark organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 29. Denmark organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 30. Sweden organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 31. Sweden organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 32. Norway organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 33. Norway organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 34. Asia Pacific organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
• Table 35. Asia Pacific organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 36. Asia Pacific organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 37. Japan organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 38. Japan organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 39. China organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 40. China organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 41. India organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 42. India organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 43. Australia organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 44. Australia organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 45. South Korea organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 46. South Korea organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 47. Thailand organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 48. Thailand organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 49. Latin America organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
• Table 50. Latin America organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 51. Latin America organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 52. Brazil organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 53. Brazil organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 54. Argentina organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 55. Argentina organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 56. Middle East & Africa Organ transplant immunosuppressant drugs market, by country, 2018 - 2030 (USD Million)
• Table 57. Middle East & Africa organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 58. Middle East & Africa organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 59. South Africa organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 60. South Africa organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 61. Saudi Arabia organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 62. Saudi Arabia organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 63. UAE organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 64. UAE organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)
• Table 65. Kuwait organ transplant immunosuppressant drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 66. Kuwait organ transplant immunosuppressant drugs market, by transplant type, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Organ transplant immunosuppressant drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Drug class and transplant type outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 Organ transplant immunosuppressant drugs market dynamics
• Fig. 12 Organ transplant immunosuppressant drugs market: Porter's five forces analysis
• Fig. 13 Organ transplant immunosuppressant drugs market: PESTLE analysis
• Fig. 14 Organ transplant immunosuppressant drugs market: Drug class segment dashboard
• Fig. 15 Organ transplant immunosuppressant drugs market: Drug class market share analysis, 2024 & 2030
• Fig. 16 Calcineurin inhibitors market, 2018 - 2030 (USD Million)
• Fig. 17 Antiproliferative agents market, 2018 - 2030 (USD Million)
• Fig. 18 mTOR inhibitor market, 2018 - 2030 (USD Million)
• Fig. 19 Steroids market, 2018 - 2030 (USD Million)
• Fig. 20 Other drug classes market, 2018 - 2030 (USD Million)
• Fig. 21 Organ transplant immunosuppressant drugs market: Transplant type segment dashboard
• Fig. 22 Organ transplant immunosuppressant drugs market: Transplant type market share analysis, 2024 & 2030
• Fig. 23 Kidney market, 2018 - 2030 (USD Million)
• Fig. 24 Liver market, 2018 - 2030 (USD Million)
• Fig. 25 Heart market, 2018 - 2030 (USD Million)
• Fig. 26 Lung market, 2018 - 2030 (USD Million)
• Fig. 27 Pancreas market, 2018 - 2030 (USD Million)
• Fig. 28 Other transplant types market, 2018 - 2030 (USD Million)
• Fig. 29 Organ transplant immunosuppressant drugs market revenue, by region
• Fig. 30 Regional marketplace: Key takeaways
• Fig. 31 Regional marketplace: Key takeaways
• Fig. 32 North America organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 33 US country dynamics
• Fig. 34 US organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 35 Canada country dynamics
• Fig. 36 Canada organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 37 Mexico country dynamics
• Fig. 38 Mexico organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 39 Europe organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 40 UK country dynamics
• Fig. 41 UK organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 42 Germany country dynamics
• Fig. 43 Germany organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 44 France country dynamics
• Fig. 45 France organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 46 Italy country dynamics
• Fig. 47 Italy organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 48 Spain country dynamics
• Fig. 49 Spain organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 50 Denmark country dynamics
• Fig. 51 Denmark organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 52 Sweden country dynamics
• Fig. 53 Sweden organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 54 Norway country dynamics
• Fig. 55 Norway organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 56 Asia Pacific organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 57 Japan country dynamics
• Fig. 58 Japan organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 59 China country dynamics
• Fig. 60 China organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 61 India country dynamics
• Fig. 62 India organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 63 Australia country dynamics
• Fig. 64 Australia organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 65 South Korea country dynamics
• Fig. 66 South Korea organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 67 Thailand country dynamics
• Fig. 68 Thailand organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 69 Latin America organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 70 Brazil country dynamics
• Fig. 71 Brazil organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 72 Argentina country dynamics
• Fig. 73 Argentina organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 74 MEA organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 75 South Africa country dynamics
• Fig. 76 South Africa organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia country dynamics
• Fig. 78 Saudi Arabia organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 79 UAE country dynamics
• Fig. 80 UAE organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 81 Kuwait country dynamics
• Fig. 82 Kuwait organ transplant immunosuppressant drugs market, 2018 - 2030 (USD Million)
• Fig. 83 Company categorization
• Fig. 84 Company market position analysis
• Fig. 85 Strategic framework

Organ Transplant Immunosuppressant Drugs Market Growth & Trends:

The global organ transplant immunosuppressant drugs market size is estimated to reach USD 7.24 billion by 2030, registering a CAGR of 4.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing patient population requiring organ transplantations and increasing approval of novel products are the factors driving the market growth. However, the high procedural cost of transplantations, the disproportion in the supply and demand for organs, and uncertain reimbursement scenario are the major factors restraining the market growth.

According to the Health Resources & Services Administration and the U.S. Department of Health and Human Services, more than 113,000 people were in need of transplants as of January 2019 and 36,528 transplants were performed in 2018. Hence, there is huge demand for organ transplants that will further boost the market. Kidney transplant held the largest market share in the transplant segment and is expected to retain its leading position through the forecast period. This can be attributed to increasing demand and comparatively better availability of kidneys than other organs.

Among the drug classes, the calcineurin inhibitors are expected to dominate the global organ transplant immunosuppressant drugs market through the forecast period. There are two drugs in this drug class, Prograf (tacrolimus) and Neoral/Sandimmune (cyclosporine). Although these effective immunosuppressants have been used in kidney transplant recipients for more than 20 years, they hold extensive toxicity profiles. Asia Pacific is expected to show the highest CAGR, while North America is expected to hold the largest share during the forecast period.

Organ Transplant Immunosuppressant Drugs Market Report Highlights:

• Calcineurin inhibitors are expected to command the largest market share in the drug class segment. Calcineurin inhibitors inhibit the activation action of T-cells of the immune system by the enzyme calcineurin.
• Calcineurin inhibitors such as tacrolimus and cyclosporine are the cornerstone of immunosuppression for kidney transplantation. In more than 85% cases of kidney transplant, tacrolimus is prescribed as a part of the patients' maintenance immunosuppressive regimen.
• Based on transplant type, the kidney transplant held the largest market share of 49.1% in 2024, due to the increasing demand for kidney replacement procedures
• Asia Pacific regional market is expected to demonstrate the fastest growth over the forecast period due to rising per capita healthcare expenditure, improving healthcare infrastructure, and increasing demand for organ transplantations in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Transplant Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Organ Transplant Immunosuppressant Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Organ Transplant Immunosuppressant Drugs Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Calcineurin Inhibitors
  • 4.4.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
• 4.5. Antiproliferative Agents
  • 4.5.1. Antiproliferative Agents Market, 2018 - 2030 (USD Million)
• 4.6. mTOR Inhibitor
  • 4.6.1. mTOR Inhibitor Market, 2018 - 2030 (USD Million)
• 4.7. Steroids
  • 4.7.1. Steroids Market, 2018 - 2030 (USD Million)
• 4.8. Other Drug Classes
  • 4.8.1. Other Drug Classes Market, 2018 - 2030 (USD Million)

Chapter 5. Organ Transplant Immunosuppressant Drugs Market: Transplant Type Business Analysis

• 5.1. Transplant Type Market Share, 2024 & 2030
• 5.2. Transplant Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Transplant Type, 2018 to 2030 (USD Million)
• 5.4. Kidney
  • 5.4.1. Kidney Market, 2018 - 2030 (USD Million)
• 5.5. Liver
  • 5.5.1. Liver Market, 2018 - 2030 (USD Million)
• 5.6. Heart
  • 5.6.1. Heart Market, 2018 - 2030 (USD Million)
• 5.7. Lung
  • 5.7.1. Lung Market, 2018 - 2030 (USD Million)
• 5.8. Pancreas
  • 5.8.1. Pancreas Market, 2018 - 2030 (USD Million)
• 5.9. Other Transplant Types
  • 5.9.1. Other Transplant Types Market, 2018 - 2030 (USD Million)

Chapter 6. Organ Transplant Immunosuppressant Drugs Market: Regional Estimates & Trend Analysis by Drug Class and Transplant Type

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.4. North America
  • 6.4.1. North America Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Regulatory Framework
    • 6.4.2.3. Competitive Insights
    • 6.4.2.4. U.S. Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Regulatory Framework
    • 6.4.3.3. Competitive Insights
    • 6.4.3.4. Canada Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Regulatory Framework
    • 6.4.4.3. Competitive Insights
    • 6.4.4.4. Mexico Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Regulatory Framework
    • 6.5.2.3. Competitive Insights
    • 6.5.2.4. UK Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Regulatory Framework
    • 6.5.3.3. Competitive Insights
    • 6.5.3.4. Germany Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Regulatory Framework
    • 6.5.4.3. Competitive Insights
    • 6.5.4.4. France Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Regulatory Framework
    • 6.5.5.3. Competitive Insights
    • 6.5.5.4. Italy Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Regulatory Framework
    • 6.5.6.3. Competitive Insights
    • 6.5.6.4. Spain Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. Norway
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Regulatory Framework
    • 6.5.7.3. Competitive Insights
    • 6.5.7.4. Norway Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Regulatory Framework
    • 6.5.8.3. Competitive Insights
    • 6.5.8.4. Denmark Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5.9. Sweden
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Regulatory Framework
    • 6.5.9.3. Competitive Insights
    • 6.5.9.4. Sweden Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Regulatory Framework
    • 6.6.2.3. Competitive Insights
    • 6.6.2.4. Japan Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Regulatory Framework
    • 6.6.3.3. Competitive Insights
    • 6.6.3.4. China Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Regulatory Framework
    • 6.6.4.3. Competitive Insights
    • 6.6.4.4. India Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Regulatory Framework
    • 6.6.5.3. Competitive Insights
    • 6.6.5.4. Australia Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Regulatory Framework
    • 6.6.6.3. Competitive Insights
    • 6.6.6.4. South Korea Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Regulatory Framework
    • 6.6.7.3. Competitive Insights
    • 6.6.7.4. Thailand Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Regulatory Framework
    • 6.7.2.3. Competitive Insights
    • 6.7.2.4. Brazil Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Regulatory Framework
    • 6.7.3.3. Competitive Insights
    • 6.7.3.4. Argentina Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. MEA Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Regulatory Framework
    • 6.8.2.3. Competitive Insights
    • 6.8.2.4. South Africa Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Regulatory Framework
    • 6.8.3.3. Competitive Insights
    • 6.8.3.4. Saudi Arabia Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Regulatory Framework
    • 6.8.4.3. Competitive Insights
    • 6.8.4.4. UAE Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Regulatory Framework
    • 6.8.5.3. Competitive Insights
    • 6.8.5.4. Kuwait Organ Transplant Immunosuppressant Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. Astellas Pharma d.o.o.
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Sanofi
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Accord Healthcare
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Novartis AG
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Viatris Inc.
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. F. Hoffmann-La Roche Ltd
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. GlaxoSmithKline plc.
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Veloxis Pharmaceuticals, Inc.
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Bristol-Myers Squibb Company
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives